Division of Environmental Health Sciences, New York State Department of Health, Albany, New York 12201, USA.
Chem Res Toxicol. 2010 Apr 19;23(4):788-801. doi: 10.1021/tx900436m.
A targeted liquid chromatography/tandem mass spectrometry-based metabolomics type approach, employing a triple stage quadrupole mass spectrometer in the product ion scan and selected reaction monitoring modes, was established to profile 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), and their principal metabolites in the urine of omnivores. A mixed-mode reverse phase cation exchange resin enrichment procedure was employed to isolate MeIQx and its oxidized metabolites, 2-amino-8-(hydroxymethyl)-3-methylimidazo[4,5-f]quinoxaline (8-CH(2)OH-IQx) and 2-amino-3-methylimidazo[4,5-f]quinoxaline-8-carboxylic acid (IQx-8-COOH), which are produced by cytochrome P450 1A2 (P450 1A2). The phase II conjugates N(2)-(beta-1-glucosiduronyl)-2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline and N(2)-(3,8-dimethylimidazo[4,5-f]quinoxalin-2-yl)-sulfamic acid were measured indirectly, following acid hydrolysis to form MeIQx. The enrichment procedure permitted the simultaneous analysis of PhIP, N(2)-(beta-1-glucosidurony1)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, N3-(beta-1-glucosidurony1)-2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 2-amino-1-methyl-6-(4'-hydroxy)-phenylimidazo[4,5-b]pyridine (4'-HO-PhIP), and the isomeric N(2)- and N3-glucuronide conjugates of the carcinogenic metabolite, 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (HONH-PhIP), which is formed by P450 1A2. The limit of quantification (LOQ) for MeIQx, PhIP, and 4'-HO-PhIP was approximately 5 pg/mL; the LOQ values for 8-CH(2)OH-IQx and IQx-8-COOH were, respectively, <15 and <25 pg/mL, and the LOQ values for the glucuronide conjugates of PhIP and HONH-PhIP were 50 pg/mL. The metabolism was extensive; less than 9% of the dose was eliminated in urine as unaltered MeIQx, and <1% was eliminated as unaltered PhIP. Phase II conjugates of the parent amines accounted for up to 12% of the dose of MeIQx and up to 2% of the dose of PhIP. 8-CH(2)OH-IQx and IQx-8-COOH accounted for up to 76% of the dose of MeIQx, and the isomeric glucuronide conjugates of HONH-PhIP accounted for up to 33% of the dose of PhIP that were eliminated in urine within 10 h of meat consumption. P450 1A2 significantly contributes to the metabolism of both HAAs but with marked differences in substrate specificity. P450 1A2 primarily catalyzes the detoxification of MeIQx by oxidation of the 8-methyl group, whereas it catalyzes the bioactivation of PhIP by oxidation of the exocyclic amine group.
采用三重四极杆质谱仪在产物离子扫描和选择反应监测模式下建立了一种靶向液相色谱/串联质谱代谢组学方法,用于分析杂食者尿液中的 2-氨基-3,8-二甲基咪唑[4,5-f]喹喔啉(MeIQx)、2-氨基-1-甲基-6-苯基咪唑[4,5-b]吡啶(PhIP)及其主要代谢物。采用混合模式反相阳离子交换树脂富集程序分离 MeIQx 及其氧化代谢物 2-氨基-8-(羟甲基)-3-甲基咪唑[4,5-f]喹喔啉(8-CH(2)OH-IQx)和 2-氨基-3-甲基咪唑[4,5-f]喹喔啉-8-羧酸(IQx-8-COOH),这些代谢物由细胞色素 P450 1A2(P450 1A2)产生。相 II 缀合物 N(2)-(β-1-葡糖醛酸基)-2-氨基-3,8-二甲基咪唑[4,5-f]喹喔啉和 N(2)-(3,8-二甲基咪唑[4,5-f]喹喔啉-2-基)-氨基磺酸通过酸水解形成 MeIQx 后间接测量。该富集程序允许同时分析 PhIP、N(2)-(β-1-葡糖醛酸基)-2-氨基-1-甲基-6-苯基咪唑[4,5-b]吡啶、N3-(β-1-葡糖醛酸基)-2-氨基-1-甲基-6-苯基咪唑[4,5-b]吡啶、2-氨基-1-甲基-6-(4'-羟基)-苯基咪唑[4,5-b]吡啶(4'-HO-PhIP)和致癌代谢物 2-羟基氨基-1-甲基-6-苯基咪唑[4,5-b]吡啶(HONH-PhIP)的异构 N(2)-和 N3-葡萄糖醛酸缀合物,这些物质由 P450 1A2 形成。MeIQx、PhIP 和 4'-HO-PhIP 的定量下限(LOQ)约为 5 pg/mL;8-CH(2)OH-IQx 和 IQx-8-COOH 的 LOQ 值分别为 <15 和 <25 pg/mL,PhIP 和 HONH-PhIP 的葡萄糖醛酸缀合物的 LOQ 值为 50 pg/mL。代谢非常广泛;小于 9%的剂量以未改变的 MeIQx 的形式从尿液中排出,小于 1%的剂量以未改变的 PhIP 的形式排出。母体胺的相 II 缀合物占 MeIQx 剂量的高达 12%,占 PhIP 剂量的高达 2%。MeIQx 剂量的高达 76%是 8-CH(2)OH-IQx 和 IQx-8-COOH,PhIP 剂量的高达 33%是 HONH-PhIP 的异构葡萄糖醛酸缀合物,这些物质在食用肉类后 10 小时内从尿液中排出。细胞色素 P450 1A2 显著参与了两种 HAAs 的代谢,但在底物特异性方面存在显著差异。P450 1A2 主要通过氧化 8-甲基基团来催化 MeIQx 的解毒,而通过氧化外环胺基团来催化 PhIP 的生物活化。